TW202302094A - 用於治療激躁之方法及組合物 - Google Patents

用於治療激躁之方法及組合物 Download PDF

Info

Publication number
TW202302094A
TW202302094A TW111107146A TW111107146A TW202302094A TW 202302094 A TW202302094 A TW 202302094A TW 111107146 A TW111107146 A TW 111107146A TW 111107146 A TW111107146 A TW 111107146A TW 202302094 A TW202302094 A TW 202302094A
Authority
TW
Taiwan
Prior art keywords
pharmaceutically acceptable
acceptable salt
dosage form
dexmedetomidine
therapeutically effective
Prior art date
Application number
TW111107146A
Other languages
English (en)
Chinese (zh)
Inventor
維沃 麥可 德
弗里索 波斯塔瑪
大衛 克里山 漢利
維什可瑪 庫庫瑪努
薩柏翰杜 賽斯
戴恩許 庫馬爾 德哈爾
Original Assignee
美商百歐克斯賽爾治療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商百歐克斯賽爾治療公司 filed Critical 美商百歐克斯賽爾治療公司
Publication of TW202302094A publication Critical patent/TW202302094A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW111107146A 2021-02-26 2022-02-25 用於治療激躁之方法及組合物 TW202302094A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163154281P 2021-02-26 2021-02-26
US63/154,281 2021-02-26

Publications (1)

Publication Number Publication Date
TW202302094A true TW202302094A (zh) 2023-01-16

Family

ID=83048476

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111107146A TW202302094A (zh) 2021-02-26 2022-02-25 用於治療激躁之方法及組合物

Country Status (7)

Country Link
US (2) US20240139169A1 (https=)
EP (1) EP4297871A4 (https=)
JP (1) JP2024507991A (https=)
CN (1) CN117412747A (https=)
CA (1) CA3208828A1 (https=)
TW (1) TW202302094A (https=)
WO (1) WO2022183029A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL267689B2 (en) 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
BR112020026672A2 (pt) 2018-06-27 2021-03-30 Bioxcel Therapeutics, Inc. Formulações de filme contendo dexmedetomidina e métodos para produzi-las
BR112022000992A2 (pt) 2019-07-19 2022-06-14 Arx Llc Regimes de tratamento de dexmedetomidina não sedantes
EP4078055B1 (en) * 2019-12-16 2025-03-12 Northwestern University Method for forming a circular pellet
TW202416979A (zh) * 2022-08-31 2024-05-01 美商百歐克斯賽爾治療公司 用於治療急性壓力症之方法及組合物
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
WO2024211911A1 (en) * 2023-04-07 2024-10-10 Oaktree Fund Administration, Llc Methods for treating depressive states
EP4731214A1 (en) * 2023-06-23 2026-04-29 BioXcel Therapeutics, Inc. Dexmedetomidine treatment regimens

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1138164A1 (ru) * 1963-04-25 1985-02-07 Shadurskij Konstantin S Антигистаминное средство "димебон
US20070117834A1 (en) * 2005-10-04 2007-05-24 David Hung Methods and compositions for treating Huntington's disease
MX2010001218A (es) * 2007-08-01 2010-04-07 Medivation Neurology Inc Metodos y composiciones para tratamiento contra esquizofrenia mediante uso de terapia combinada de agentes antipsicoticos.
JP2010540454A (ja) * 2007-09-21 2010-12-24 アカディア ファーマシューティカルズ，インコーポレーテッド ピマバンセリンと他の薬剤との併用投与
WO2009039461A2 (en) * 2007-09-21 2009-03-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
EP2340254B8 (en) * 2008-09-15 2014-05-21 Biovista, Inc. Compositions and methods for treating epilepsy
TR200903014A1 (tr) * 2009-04-17 2010-11-22 Sanovel İlaç San. Ve Ti̇c. A.Ş. Oral yolla dağılan dimebolin bileşimleri.
WO2011039686A1 (en) * 2009-09-30 2011-04-07 Pfizer Inc. Latrepirdine oral sustained release dosage forms
US20120202823A1 (en) * 2010-12-23 2012-08-09 Alkermes, Inc. Multi-API Loading Prodrugs
IL267689B2 (en) * 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
BR112022000992A2 (pt) * 2019-07-19 2022-06-14 Arx Llc Regimes de tratamento de dexmedetomidina não sedantes

Also Published As

Publication number Publication date
EP4297871A4 (en) 2025-01-01
EP4297871A1 (en) 2024-01-03
CA3208828A1 (en) 2022-09-01
CN117412747A (zh) 2024-01-16
US20250228833A1 (en) 2025-07-17
JP2024507991A (ja) 2024-02-21
WO2022183029A1 (en) 2022-09-01
US20240139169A1 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
TW202302094A (zh) 用於治療激躁之方法及組合物
JP6198370B2 (ja) 経口投与剤形
KR101682965B1 (ko) 구강내 붕괴성 피복 정제
RU2572692C2 (ru) Сублингвальные композиции дексмедетомидина и способы их применения
JP2021102654A (ja) 激越の治療のための舌下デクスメデトミジンの使用
ES2908977T3 (es) Forma de dosificación farmacéutica sólida para liberar en la cavidad oral al menos dos ingredientes farmacéuticos activos
JP2013539790A (ja) メマンチンを含む鎮咳組成物
EP1750677B1 (en) Oral therapeutic compound delivery system
KR20160143792A (ko) 이온 통로 활성제 및 사용 방법
MXPA06000529A (es) Formulaciones farmaceuticas utiles para inhibir la secrecion de acido y metodos para elaborarlas y utilizarlas.
KR20180097581A (ko) 1-(3-(2-(1-벤조티오펜-5-일)에톡시)프로필)아제티딘-3-올 또는 그 염을 포함하는 정제
US20130274342A1 (en) Compositions and methods for treating cough
TW202228682A (zh) 使用右美托咪啶(dexmedetomidine)鹽酸鹽治療躁鬱症及精神病
JP2016535794A (ja) 急速崩壊性製剤及びその使用法
JP6061924B2 (ja) 口腔内分散性製剤
JP2025529123A (ja) 急性ストレス障害を処置するための方法及び組成物
US9155704B1 (en) More palatable, bioequivalent pharmaceutical composition of carprofen
US20180318228A1 (en) Method for a slow release of drugs from orally dissolving capsules
JP2019515045A (ja) 甲状腺ホルモン又はそのアナログを提供する組成物及び方法
JP2018516274A (ja) コルヒチンサリチル酸塩およびこの利用
JP2006076956A (ja) 胃炎の治療・予防用配合剤
Nagpal et al. Patent innovations in fast dissolving/disintegrating dosage forms
WO2025128666A1 (en) Combination of latrepirdine and a pharmacokinetic stabilizer
US20080008772A1 (en) Narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
Konde Formulation and Evaluation of Orodispersible Tablets of Lansoprazole